Faculty Collaboration Database

The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging 2002;19(1):1-10

Date

04/04/2002

Pubmed ID

11929323

DOI

10.2165/00002512-200219010-00001

Scopus ID

2-s2.0-0036235345 (requires institutional sign-in at Scopus site)   22 Citations

Abstract

There is strong evidence to indicate that individuals who sustain a hip fracture are at a greater risk of developing another. The management of such patients should include efforts to prevent future fractures, including prescribing medications that have been shown to lower hip fracture risk. Such therapies that are currently available include calcium and vitamin D supplementation, alendronic acid and risedronic acid. In addition, there is epidemiological evidence to indicate that estrogen may also decrease the risk of hip fracture. Parathyroid hormone is another agent that has shown promise in this regard and is likely to be available for clinical use in the near future. However, the rates of utilisation of these therapies among patients with hip fractures are low. It is important to emphasise that secondary prevention of hip fractures should be an integral part of the management of individuals who sustain hip fractures.

Author List

Kamel HK, Duthie EH

Author

Edmund H. Duthie MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Accidental Falls
Alendronate
Calcium
Estrogens
Etidronic Acid
Hip Fractures
Hip Prosthesis
Humans
Parathyroid Hormone
Risk Factors
Vitamin D